- Patients using concomitant migraine preventive medications reported significant improvement in acute migraine pain 2 hours after taking lasmiditan compared with placebo.
Why this matters
- Results come from a subanalysis of 2 randomized trials of lasmiditan, which demonstrated efficacy in reducing pain and symptoms from acute migraine but did not examine efficacy in patients who took preventive medications and those who did not.
- Post hoc analysis of 2 randomized, double-blind, placebo-controlled phase 3 studies (n= 3981; episodic migraine with/without aura).
- Treatment groups received placebo or oral lasmiditan (50, 100, or 200 mg).
- Funding: Eli Lilly and Company, Indianapolis, Indiana, USA.
- 17.5% of the patients received migraine preventive treatments.
- Of all preventives used, most common were antiepileptics (35%), beta blockers (32.3%), and antidepressants (25.5%).
- All doses of lasmiditan (vs placebo) significantly increased (P<.05 the percentage of patients with freedom from pain and most bothersome symptom at hours.>
- Groups receiving/not receiving preventive medications showed no significant differences for pain- and MBS-free outcomes at 2 hours (all interaction, P>.1).
- Lasmiditan (50 mg) was included in only 1 trial.
Coauthored with Chitra Ravi, MPharm